Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126556831 | 12655683 | 1 | I | 20140701 | 20151116 | 20160816 | 20160816 | PER | US-ROCHE-1661991 | ROCHE | 50.00 | YR | F | Y | 0.00000 | 20160816 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126556831 | 12655683 | 1 | PS | PEGASYS | PEGINTERFERON ALFA-2A | 1 | Oral | U | 103964 | ||||||||||
| 126556831 | 12655683 | 2 | SS | RIBAVIRIN. | RIBAVIRIN | 1 | Oral | U | 21511 | ||||||||||
| 126556831 | 12655683 | 3 | SS | SOFOSBUVIR | SOFOSBUVIR | 1 | Oral | U | 0 | 400 | MG | TABLET |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126556831 | 12655683 | 1 | Chronic hepatitis C |
| 126556831 | 12655683 | 2 | Chronic hepatitis C |
| 126556831 | 12655683 | 3 | Chronic hepatitis C |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126556831 | 12655683 | Vision blurred | |
| 126556831 | 12655683 | Vitreous floaters |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126556831 | 12655683 | 1 | 20140623 | 20140701 | 0 | |
| 126556831 | 12655683 | 2 | 20140623 | 20140701 | 0 | |
| 126556831 | 12655683 | 3 | 20140623 | 20140701 | 0 |